

3 June 2019

Appointment of Parafix as Manufacturing Partner

OBJ Limited (ASX: OBJ) is pleased to announce continued progress of the Bodyguard program, with Board approval of the updated Business Plan and subsequent appointment of Parafix Tapes and Conversions Ltd (“Parafix”) as chosen manufacturing partner for the Kneeguard patch.

The Business Plan has a defined objective to commercialise OBJ’s patch technology under OBJ’s own brand. It outlines a number of strategic imperatives and expectations, with best-in-class manufacture as a key short-term milestone. To this end, and after an extensive audit process, the Company has now entered into a Manufacturing Agreement with Parafix UK to manufacture the Kneeguard product. Production of commercial prototypes and manufacturing validation will commence in the coming weeks. The Manufacturing Agreement outlines the working relationship between both parties and enables the Company to move forward with its regulatory requirements for the product.

Parafix are a leading converter of adhesive products and medical devices, across a diverse range of industries, and a preferred converter for healthcare conglomerate 3M. They are headquartered in the United Kingdom with satellite facilities in Eastern Europe. All their facilities are suitably ISO 13485 compliant and FDA registered. Their capabilities extend to adhesive tapes, films, device assembly and in-line printing and packaging.

The Board is pleased to be partnering with Parafix and will be looking to draw on their significant expertise in materials, production economics and quality assurance to assist the Company’s push towards a targeted commercial launch of the Kneeguard product in Q2 2020 (subject to regulatory approvals).

Directors

Mr Antonio Varano
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Cameron Reynolds
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered

Office:
284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
www.obj.com.au
ABN: 72 056 482 636

ABOUT OBJ

OBJ develops proprietary magnetic microarray drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

ABOUT OBJ’S TECHNOLOGIES

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

3 June 2019

Complex 3-D magnetic fields produced by low cost microarrays or powered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost microarray film technology that utilises diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

FORWARD-LOOKING STATEMENTS

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward-looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

Directors

Mr Antonio Varano
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Cameron Reynolds
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered

Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
www.obj.com.au
ABN: 72 056 482 636

For more information:

Matthew Wright
matt@nwrcommunications.com.au
Phone: +61 451 896 420